Covered recipient · General Payments record
PAUL A HARTLEY
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$1,894.42
129 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,894.42 | 129 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $357.38 | 23 |
| Novo Nordisk Inc | $283.28 | 19 |
| Janssen Pharmaceuticals, Inc | $198.58 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $151.66 | 11 |
| SANOFI-AVENTIS U.S. LLC | $129.09 | 10 |
| AbbVie Inc. | $98.31 | 6 |
| GlaxoSmithKline, LLC. | $87.23 | 5 |
| Lilly USA, LLC | $82.37 | 5 |
| Bayer HealthCare Pharmaceuticals Inc. | $78.04 | 5 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $71.25 | 5 |
| Merck Sharp & Dohme Corporation | $50.52 | 4 |
| Amarin Pharma Inc. | $45.71 | 3 |
| BOSTON SCIENTIFIC CORPORATION | $40.33 | 1 |
| Biohaven Pharmaceuticals, Inc. | $29.48 | 2 |
| AstraZeneca Pharmaceuticals LP | $28.82 | 2 |
| Astellas Pharma US Inc | $23.69 | 1 |
| Amgen Inc. | $19.02 | 1 |
| Radius Health, Inc. | $18.94 | 1 |
| Abbott Laboratories | $16.96 | 1 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $15.93 | 1 |
| RedHill Biopharma Inc. | $15.29 | 1 |
| Alnylam Pharmaceuticals Inc. | $15.18 | 1 |
| Esperion Therapeutics, Inc. | $13.90 | 1 |
| Horizon Therapeutics plc | $11.76 | 1 |
| DEXCOM, INC. | $11.70 | 1 |
Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PAUL A HARTLEY
NPI 1417911587 · CMS profile ID 154543
Allopathic & Osteopathic Physicians / Internal Medicine
UNIONTOWN, PA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1417911587?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PAUL A HARTLEY, NPI 1417911587, CMS profile ID 154543. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417911587?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). PAUL A HARTLEY, NPI 1417911587, CMS profile ID 154543. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417911587?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- PAUL A HARTLEY, NPI 1417911587, CMS profile ID 154543, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1417911587?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
129 matching records · $1,894.42 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 129.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $15.43 | 07/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832725759 | CMS |
| BOSTON SCIENTIFIC CORPORATION | $40.33 | 07/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793761903 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12.40 | 07/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 850110415 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.79 | 07/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763784898 | CMS |
| Janssen Pharmaceuticals, Inc | $9.50 | 07/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788215969 | CMS |
| SANOFI-AVENTIS U.S. LLC | $12.30 | 07/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843458925 | CMS |
| PFIZER INC. | $13.65 | 07/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832777801 | CMS |
| GlaxoSmithKline, LLC. | $12.05 | 06/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803110581 | CMS |
| Janssen Pharmaceuticals, Inc | $0.45 | 06/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788215983 | CMS |
| Novo Nordisk Inc | $13.34 | 06/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811182697 | CMS |
| PFIZER INC. | $15.72 | 06/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833403733 | CMS |
| SANOFI-AVENTIS U.S. LLC | $12.84 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843458921 | CMS |
| Novo Nordisk Inc | $16.83 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811182692 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $11.85 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 850222077 | CMS |
| PFIZER INC. | $17.03 | 06/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832582725 | CMS |
| Novo Nordisk Inc | $14.15 | 06/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811698611 | CMS |
| Janssen Pharmaceuticals, Inc | $13.72 | 06/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788215953 | CMS |
| AbbVie Inc. | $18.15 | 05/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794763761 | CMS |
| Novo Nordisk Inc | $15.90 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811596377 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.46 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 850370963 | CMS |
| GlaxoSmithKline, LLC. | $21.09 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802139555 | CMS |
| Amgen Inc. | $19.02 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826408731 | CMS |
| Lilly USA, LLC | $18.18 | 05/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818685917 | CMS |
| Amarin Pharma Inc. | $14.56 | 05/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815281795 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $15.93 | 05/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851918241 | CMS |
| DEXCOM, INC. | $11.70 | 05/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845280355 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.41 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763784900 | CMS |
| GlaxoSmithKline, LLC. | $20.71 | 05/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802107187 | CMS |
| Janssen Pharmaceuticals, Inc | $11.19 | 05/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788215977 | CMS |
| Astellas Pharma US Inc | $23.69 | 05/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821356319 | CMS |
| Novo Nordisk Inc | $17.95 | 04/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810799775 | CMS |
| SANOFI-AVENTIS U.S. LLC | $12.38 | 04/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843458903 | CMS |
| SANOFI-AVENTIS U.S. LLC | $11.97 | 04/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843458913 | CMS |
| PFIZER INC. | $22.21 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832550157 | CMS |
| Novo Nordisk Inc | $16.43 | 04/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811596374 | CMS |
| Lilly USA, LLC | $14.54 | 04/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818720199 | CMS |
| PFIZER INC. | $9.46 | 04/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833459495 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.01 | 04/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763784902 | CMS |
| Janssen Pharmaceuticals, Inc | $14.85 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788215979 | CMS |
| PFIZER INC. | $16.37 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833407163 | CMS |
| Radius Health, Inc. | $18.94 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830747435 | CMS |
| Alnylam Pharmaceuticals Inc. | $15.18 | 04/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 828518513 | CMS |
| Janssen Pharmaceuticals, Inc | $11.84 | 04/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788215961 | CMS |
| AbbVie Inc. | $16.38 | 04/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794763757 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.85 | 04/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829969629 | CMS |
| PFIZER INC. | $15.94 | 03/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833519419 | CMS |
| AbbVie Inc. | $13.97 | 03/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794763753 | CMS |
| PFIZER INC. | $16.77 | 03/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832633831 | CMS |
| Novo Nordisk Inc | $12.91 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811459557 | CMS |
| Merck Sharp & Dohme Corporation | $13.31 | 03/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848611295 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $728,944.08 | 209 |
| PY2024 | Recipient | $14,481.00 | 4 |
| PY2024 | Principal investigator | $1,113,532.79 | 43 |
| PY2023 | Recipient | $1,786.58 | 5 |
| PY2023 | Principal investigator | $757,362.96 | 58 |
| PY2022 | Recipient | $26,861.00 | 5 |
| PY2022 | Principal investigator | $547,518.21 | 75 |
| PY2021 | Recipient | $84.15 | 1 |
| PY2021 | Principal investigator | $671,018.24 | 71 |
| PY2020 | Recipient | $1,459.90 | 3 |
| PY2020 | Principal investigator | $585,105.54 | 100 |
| PY2019 | Recipient | $2,793.81 | 2 |
| PY2019 | Principal investigator | $448,660.93 | 65 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
209 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $837.00 | 12/31/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735940 |
| Principal investigator 1 | Eli Lilly and Company | $25,042.00 | 12/29/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL | No dispute reported | 06/30/2026 | 1187887956 |
| Principal investigator 1 | PFIZER INC. | $5,762.00 | 12/24/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228736177 |
| Principal investigator 1 | PFIZER INC. | $3,520.00 | 12/19/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228745708 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,150.00 | 12/17/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc Admin Office | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802540 |
| Principal investigator 1 | ModernaTX, Inc. | $1,400.00 | 12/17/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011154 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 12/17/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011160 |
| Principal investigator 1 | ModernaTX, Inc. | $1,245.00 | 12/17/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011180 |
| Principal investigator 1 | ModernaTX, Inc. | $1,430.00 | 12/17/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011196 |
| Principal investigator 1 | ModernaTX, Inc. | $750.00 | 12/17/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011204 |
| Principal investigator 1 | PFIZER INC. | $8,370.00 | 12/17/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228723958 |
| Principal investigator 1 | PFIZER INC. | $25,110.00 | 12/16/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735581 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,403.00 | 12/09/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc Admin Office | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802538 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,338.48 | 12/02/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220994547 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631061 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 12/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631063 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631065 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631067 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631069 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631071 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631073 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220631099 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $395.00 | 12/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220792659 |
| Principal investigator 1 | PFIZER INC. | $904.50 | 11/27/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228728065 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,750.00 | 11/14/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians - Jacob Murphy Lane | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508371 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $15,250.00 | 11/14/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians - Jacob Murphy Lane | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508375 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,000.00 | 11/14/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians - Jacob Murphy Lane | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508380 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,500.00 | 11/14/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians - Jacob Murphy Lane | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508384 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,976.00 | 11/13/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc Admin Office | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802536 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631049 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631051 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631053 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631055 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631057 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631059 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220631095 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220631097 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $395.00 | 11/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220792657 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 10/27/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220631101 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 10/27/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220631103 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $391.52 | 10/22/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220792661 |
| Principal investigator 1 | Eli Lilly and Company | $10,790.00 | 10/20/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA | No dispute reported | 06/30/2026 | 1187887954 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631037 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631039 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631041 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631043 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631045 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631047 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220631091 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220631093 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $395.00 | 10/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220792655 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,550.00 | 10/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc Admin Office | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802534 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $199.80 | 09/24/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631031 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 09/24/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631033 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $27.60 | 09/24/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631035 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 09/24/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220994545 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,271.00 | 09/18/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc Admin Office | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802532 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/17/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220792651 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,250.00 | 09/10/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc Admin Office | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220802592 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630999 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631001 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631003 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631005 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631007 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631025 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220631085 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $395.00 | 09/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220792653 |
| Principal investigator 1 | ModernaTX, Inc. | $98.80 | 08/28/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011184 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 08/26/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220631087 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 08/26/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220631089 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,693.00 | 08/06/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc Admin Office | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802530 |
| Principal investigator 1 | PFIZER INC. | $2,519.50 | 08/06/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228788598 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,600.00 | 08/05/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc Admin Office | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802528 |
| Principal investigator 1 | PFIZER INC. | $672.80 | 08/05/2025 | Non-covered Recipient Entity Preferred primary Care Physicians Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228784276 |
| Principal investigator 1 | PFIZER INC. | $289.92 | 08/04/2025 | Non-covered Recipient Entity Preferred Primary Care Phys | A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228713276 |
| Principal investigator 1 | PFIZER INC. | $131.75 | 08/04/2025 | Non-covered Recipient Entity Preferred Primary Care Phys | A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228713471 |
| Principal investigator 1 | PFIZER INC. | $757.50 | 08/04/2025 | Non-covered Recipient Entity Preferred Primary Care Phys | A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228713476 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630989 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630991 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630993 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630995 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630997 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 08/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631019 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631023 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220631083 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $395.00 | 08/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220792649 |
| Principal investigator 1 | PFIZER INC. | $3,412.80 | 07/29/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians | A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228713278 |
| Principal investigator 1 | PFIZER INC. | $125.38 | 07/29/2025 | Non-covered Recipient Entity Preferred Clinical Research | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228747256 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $255.50 | 07/28/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631027 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 07/28/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631029 |
| Principal investigator 1 | PFIZER INC. | $384.75 | 07/23/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228763657 |
| Principal investigator 1 | PFIZER INC. | $2,100.00 | 07/18/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCEDAILY ORAL DANUGLIPRON IN ADULTS WITH OVERWEIGHT OR OBESITY | No dispute reported | 06/30/2026 | 1228709997 |
| Principal investigator 1 | PFIZER INC. | $1,221.75 | 07/16/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228763022 |
| Principal investigator 1 | PFIZER INC. | $7,060.50 | 07/11/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228781581 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631009 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631011 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631013 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631015 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631017 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220631021 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 07/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220631075 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220631077 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 07/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220631079 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 07/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220631081 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $395.00 | 07/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220792647 |
| Principal investigator 1 | ModernaTX, Inc. | $2,223.00 | 06/27/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011182 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.00 | 06/26/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc Admin Office | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802526 |
| Principal investigator 1 | PFIZER INC. | $26,831.75 | 06/21/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228775765 |
| Principal investigator 1 | ModernaTX, Inc. | $16,450.20 | 06/18/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011158 |
| Principal investigator 1 | PFIZER INC. | $21,621.60 | 06/06/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228722514 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630961 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630963 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630965 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630967 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630969 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630971 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630973 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $395.00 | 06/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220792645 |
| Principal investigator 1 | ModernaTX, Inc. | $6,876.48 | 05/28/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011168 |
| Principal investigator 1 | ModernaTX, Inc. | $2,946.72 | 05/28/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011176 |
| Principal investigator 1 | ModernaTX, Inc. | $25,342.20 | 05/28/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011178 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 05/27/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630983 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 05/27/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630985 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.96 | 05/27/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630987 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,267.00 | 05/09/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc Admin Office | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802524 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630949 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630951 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630953 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630955 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630957 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630959 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $395.00 | 05/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220792643 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,500.00 | 05/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc Admin Office | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802518 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,040.00 | 05/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc Admin Office | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802520 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,200.00 | 05/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc Admin Office | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802522 |
| Principal investigator 1 | PFIZER INC. | $37,994.90 | 04/29/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228797619 |
| Principal investigator 1 | ModernaTX, Inc. | $2,223.00 | 04/28/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011172 |
| Principal investigator 1 | ModernaTX, Inc. | $7,074.08 | 04/28/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011190 |
| Principal investigator 1 | ModernaTX, Inc. | $5,446.36 | 04/28/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011192 |
| Principal investigator 1 | ModernaTX, Inc. | $1,473.36 | 04/28/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011198 |
| Principal investigator 1 | Eli Lilly and Company | $111.39 | 04/24/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBSTRUCTIVE SLEEP APNEA AND OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL | No dispute reported | 06/30/2026 | 1187887992 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $399.60 | 04/23/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630975 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,095.00 | 04/23/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630977 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $27.84 | 04/23/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630979 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.20 | 04/23/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630981 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,458.00 | 04/11/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc Admin Office | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802516 |
| Principal investigator 1 | PFIZER INC. | $24,833.75 | 04/10/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228800034 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630937 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630939 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630941 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630943 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630945 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630947 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $395.00 | 04/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220792641 |
| Principal investigator 1 | PFIZER INC. | $1,421.55 | 04/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228779621 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16,389.00 | 03/26/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc Admin Office | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802514 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 03/25/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630933 |
| Principal investigator 1 | Eli Lilly and Company | $21,743.00 | 03/24/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA | No dispute reported | 06/30/2026 | 1187887888 |
| Principal investigator 1 | ModernaTX, Inc. | $2,946.72 | 03/24/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011156 |
| Principal investigator 1 | ModernaTX, Inc. | $6,738.16 | 03/24/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011164 |
| Principal investigator 1 | ModernaTX, Inc. | $3,112.20 | 03/24/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011174 |
| Principal investigator 1 | Eli Lilly and Company | $11.16 | 03/06/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, TWO-ARM, PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED WITH INTENSIFIED CONVENTIONAL CARE IN ADULTS WHEN INITIATING TREATMENT EARLY IN THE COURSE OF TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187888692 |
| Principal investigator 1 | PFIZER INC. | $1,500.00 | 03/04/2025 | Non-covered Recipient Entity Preferred primary Care Physicians Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228789489 |
| Principal investigator 1 | Eli Lilly and Company | $9,900.00 | 03/03/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | No dispute reported | 06/30/2026 | 1187887886 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630921 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630923 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630925 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630927 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630929 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630931 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $395.00 | 03/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220792639 |
| Principal investigator 1 | PFIZER INC. | $14,500.00 | 03/01/2025 | Non-covered Recipient Entity Preferred primary Care Physicians Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228787533 |
| Principal investigator 1 | ModernaTX, Inc. | $17,784.00 | 02/27/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011162 |
| Principal investigator 1 | ModernaTX, Inc. | $2,124.20 | 02/27/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011170 |
| Principal investigator 1 | ModernaTX, Inc. | $7,350.72 | 02/27/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011194 |
| Principal investigator 1 | PFIZER INC. | $2,058.75 | 02/19/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228711210 |
| Principal investigator 1 | Eli Lilly and Company | $14,940.00 | 02/04/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, TWO-ARM, PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED WITH INTENSIFIED CONVENTIONAL CARE IN ADULTS WHEN INITIATING TREATMENT EARLY IN THE COURSE OF TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187887554 |
| Principal investigator 1 | Eli Lilly and Company | $20,702.00 | 02/04/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | No dispute reported | 06/30/2026 | 1187887952 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630905 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630907 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630909 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630911 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630913 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630915 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 02/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630917 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.00 | 02/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630919 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $395.00 | 02/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220792637 |
| Principal investigator 1 | Eli Lilly and Company | $570.00 | 01/31/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | No dispute reported | 06/30/2026 | 1187887558 |
| Principal investigator 1 | Eli Lilly and Company | $325.00 | 01/31/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | No dispute reported | 06/30/2026 | 1187888146 |
| Principal investigator 1 | Eli Lilly and Company | $819.23 | 01/31/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187888696 |
| Principal investigator 1 | ModernaTX, Inc. | $5,304.00 | 01/30/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011166 |
| Principal investigator 1 | PFIZER INC. | $837.00 | 01/29/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228799474 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16,853.00 | 01/28/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc Admin Office | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802512 |
| Principal investigator 1 | ModernaTX, Inc. | $889.20 | 01/27/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011186 |
| Principal investigator 1 | ModernaTX, Inc. | $7,434.70 | 01/27/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011188 |
| Principal investigator 1 | ModernaTX, Inc. | $7,410.00 | 01/27/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011200 |
| Principal investigator 1 | ModernaTX, Inc. | $2,946.72 | 01/27/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011202 |
| Principal investigator 1 | Eli Lilly and Company | $57,000.00 | 01/21/2025 | Non-covered Recipient Entity PREFERRED PRIMARY CARE PHYSICIANS INC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187887948 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,623.00 | 01/17/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc Admin Office | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802508 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 01/15/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228798572 |
| Principal investigator 1 | PFIZER INC. | $29,252.75 | 01/09/2025 | Non-covered Recipient Entity Preferred Primary Care Physcians Inc | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228720631 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $450.00 | 01/06/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians Inc Admin Office | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220802510 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630895 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630897 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630899 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630901 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630903 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220630935 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $395.00 | 01/01/2025 | Non-covered Recipient Entity Preferred Primary Care Physicians-Jacob Murphy Lane Suite 201 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220792635 |